- Home
- K vs VOR Comparison
K vs VOR Comparison
Compare K & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- K
- VOR
- Stock Information
- Founded
- K 1906
- VOR 2015
- Country
- K United States
- VOR United States
- Employees
- K N/A
- VOR N/A
- Industry
- K Packaged Foods
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- K Consumer Staples
- VOR Health Care
- Exchange
- K Nasdaq
- VOR Nasdaq
- Market Cap
- K 27.8B
- VOR 57.1M
- IPO Year
- K N/A
- VOR 2021
- Fundamental
- Price
- K $80.62
- VOR $0.87
- Analyst Decision
- K Hold
- VOR Strong Buy
- Analyst Count
- K 15
- VOR 7
- Target Price
- K $72.21
- VOR $11.36
- AVG Volume (30 Days)
- K 2.1M
- VOR 577.7K
- Earning Date
- K 02-06-2025
- VOR 11-07-2024
- Dividend Yield
- K 2.83%
- VOR N/A
- EPS Growth
- K 21.82
- VOR N/A
- EPS
- K 2.91
- VOR N/A
- Revenue
- K $12,799,000,000.00
- VOR N/A
- Revenue This Year
- K N/A
- VOR N/A
- Revenue Next Year
- K $2.57
- VOR N/A
- P/E Ratio
- K $26.92
- VOR N/A
- Revenue Growth
- K 15.11
- VOR N/A
- 52 Week Low
- K $52.46
- VOR $0.63
- 52 Week High
- K $81.34
- VOR $3.14
- Technical
- Relative Strength Index (RSI)
- K 48.51
- VOR 47.17
- Support Level
- K $80.56
- VOR $0.83
- Resistance Level
- K $80.88
- VOR $1.10
- Average True Range (ATR)
- K 0.27
- VOR 0.10
- MACD
- K -0.03
- VOR -0.01
- Stochastic Oscillator
- K 44.62
- VOR 22.43
About K Kellanova
Following its split from the North American cereal business in October 2023, Kellanova (previously the global snacking arm of Kellogg) has operated as a leading global manufacturer and marketer of salty snacks, snack bars, frozen breakfast fare, meat alternatives, and other packaged foods. Its offerings are manufactured in around 20 countries and marketed in more than 180 countries. Its product mix includes well-known brands such as Pringles, Cheez-It, Rice Krispies Treats, Pop-Tarts, Eggo, Nutri-Grain, and Morningstar Farms. Sales beyond its home turf account for about half of Kellanova's consolidated sales base. Mars is slated to acquire the newly independent business in a nearly $36 billion deal in the first half of calendar 2025.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.